FLGT · Fulgent Genetics, Inc.

Track FLGT — free

$19.98 +0.39 (+1.99%)

Russell 2000 member Rebalance outlook locked

Market Cap

$540.13M

27.52M

Up next

Next earnings call

Nov 1, 2026 Est · unconfirmed · in 9 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Jul 30, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 114 metrics

Revenue (TTM)

$323.93M

Trailing 12 months

Net income (TTM)

−$84.01M

Trailing 12 months

Revenue growth YoY

+4.4%

Year over year

Operating margin

-37.7%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-19.2%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$26.30M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

-8.3%

Year over year · fewer shares

Price change (1Y)

-11.6%

Trailing year

Short interest

9.3%

Latest settlement · 9.3 days to cover

View all 114 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 16.3 · calm Equity put/call 0.67

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −6%

below

Price vs 50-day avg −0%

below

RSI (14) 52

neutral

MACD trend Positive

52-week position 34%

mid-range

Volume (OBV) Bearish div.

distributing

Momentum

relative strength

Strong

1-month return +6%

trailing

6-month return +36%

trailing

YTD return −25%

this year

Relative strength +24%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $20 › 200d $21 — 200d above 50d

Institutional flow Distributing

-11% holders QoQ · +21 funds added

Insider flow Distributing

Net -$42.4K over 90 days · 100% sells

Short interest Falling

9.29% of float · ▼ -0.4% MoM · 9.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr low

142 holders — near 3-yr low, contrarian setup

Squeeze score 68

elevated · 0–100

Fundamentals

Strong

Revenue growth +2%

Y/Y

Gross margin 699%

expanding

Free cash flow $-124.2M

Buyback $75.8M

remaining

Quant / Vol

risk profile

Very High

Volatility 59%

annualized · 1-yr

Max drawdown −55%

past year

ATR 3.4%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

2 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−6% Bearish

Price vs 50-day avg

−0% Neutral

RSI (14)

52 Neutral

MACD trend

Positive Bullish

52-week position

34% Neutral

Volume (OBV)

Bearish div. Bearish

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $20 › 200d $21 — 200d above 50d

Institutional flow Distributing

-11% holders QoQ · +21 funds added

Insider flow Distributing

Net -$42.4K over 90 days · 100% sells

Short interest Falling

9.29% of float · ▼ -0.4% MoM · 9.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr low

142 holders — near 3-yr low, contrarian setup

Price context

position in its 52-week range

Range low $14 Now $20 · 34% Range high $31

vs 200-day avg -6% vs 50-day avg 0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Diagnostics & Research — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
FLGT Fulgent Genetics, Inc. this stock	$540.13M	-25.4%	+2.5%	—	9.3%
TMO Thermo Fisher Scientific Inc.	$224.08B	+3.6%	+14.5%	32.6	1.3%
DHR Danaher Corp /De/	$147.09B	-9.6%	+8.5%	37.1	1.2%
NTRA Natera, Inc.	$46.24B	+40.0%	-2.8%	—	3.0%
IQV Iqvia Holdings Inc.	$43.12B	+14.6%	+41.6%	32.1	2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

142

% held: 57.5%
Net QoQ: -1.7M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

184

View

Short & Settlement

Short Interest Falling

Shares short

2.6M

Days to cover: 9.3d
Change: -9.6K sh

View

Short Volume

Short vol %

31%

As of: Sep 1, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $19
As of: Aug 11, 2026

View

Off-Exchange

Off-exchange %

35.9%

Week of: Jul 27, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$42.4K

Buyers / Sellers: 0 / 2

Buyers Sellers

View

Financials

Revenue (FY)

$322.7M

Net income (FY): $-60.5M

View

Buybacks

Authorized

$250.0M

Remaining: $75.8M

Spent Remaining

View

Filings

SEC Filings

Latest

8-K

Filed: Jul 30, 2026
This year: 11

View

Proposed Sales

Value

$18.7K

Shares: 939
Filed: Aug 27, 2026

View

Earnings & Events

Earnings Calls

Last call

Jul 30, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
FLGT	-1.8%	+5.6%	+36.3%	+1.1%	-25.4%
SPY	-0.5%	-1.2%	+12.6%	-0.7%	+11.7%
vs SPY	-1.3%	+6.9%	+23.7%	+1.8%	-37.1%

Capital returns

Buyback program · as of Jun 30, 2026

Authorized

$250.00M

Spent (derived)

$174.20M

Remaining

$75.80M

Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1674930 CUSIP 359664109 13F (30d) 114 filings 113 filers Visit website Investor relations

FLGT · Fulgent Genetics, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Versus peers

At a glance

Performance

Capital returns